Closed · PAR-24-043 · CFDA 93.121;93.213;93.242;93.273;93.279;93.853;93.865;93.866;93.867 · Discretionary

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

Varies
Award range
Closed
Status
December 14, 2024
Close date
-
Expected awards

The verdict

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.

Varies
award range
Closed
application status
93.121;93.213;93.242;93.273;93.279;93.853;93.865;93.866;93.867
CFDA program

Opportunity snapshot. This Grants.gov announcement - Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) - is cataloged under number PAR-24-043 and tied to CFDA assistance listing 93.121;93.213;93.242;93.273;93.279;93.853;93.865;93.866;93.867, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on November 2, 2023 and last updated on December 4, 2024. The funding category is Discretionary, delivered as a cooperative agreement.

Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. This opportunity closed on December 14, 2024. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.

Award Range

Varies by applicant

Close Date

December 14, 2024

Posted

November 2, 2023

Instrument

Cooperative Agreement

Description

Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Eligibility

Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH Grants Information grantsinfo@nih.gov

Key Dates

Posted November 2, 2023
Close Date December 14, 2024
Archive Date January 13, 2025
Last Updated December 4, 2024

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)", offered by National Institutes of Health. It is associated with CFDA program 93.121;93.213;93.242;93.273;93.279;93.853;93.865;93.866;93.867. Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development...
Is this opportunity still open?
No, this opportunity is closed. It closed on December 14, 2024. Check the parent program page for future funding cycles.
How much funding is available?
The award range for this opportunity is Varies by applicant.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants